Table of Contents

company-logo

Carna Biosciences, Inc., a clinical-stage biopharmaceutical company, discovers and develops drug therapies to treat unmet medical needs in Japan. Its products include kinase proteins, substrates, kinase protein assay kits, and stable cell lines, as well as biotinylated kinases to use in the study of kinase-molecule interactions. The company also offers profiling, NanoBRET TE intracellular kinase cell-based assay, protein detection and interaction, live-cell kinase assay, ClariCELL kinase cell-based assay, crystallization, weak affinity chromatography, and tyrosine kinase cell-based assay services, as well as custom production of ultra-pure proteins for crystallography. It also focuses on developing products for the treatment of various diseases, such as AS-0141, an orally bioavailable small molecule inhibitor of CDC7 kinase that is in preclinical trials to treat cancer; AS-0871, a small molecule drug for inflammatory and immune disorders, which is in Phase 1 clinical trials; and AS-1763, an orally bioavailable and non-covalent inhibitor for the treatment of chronic lymphocytic leukemia and other B cell malignancies that is in preclinical trials. The company has collaborations with Johnson & Johnson, Sierra Oncology, Sumitomo Dainippon Pharma, Gilead Sciences, and BioNova Pharmaceuticals. Carna Biosciences, Inc. was founded in 2003 and is based in Kobe, Japan.

Carna Biosciences Dividend Announcement

• Carna Biosciences does not currently offer dividends, we're keeping a close eye on its growth potential and financial developments.
• Stay tuned for updates on Carna Biosciences dividend policy and future announcements. In the meantime, explore other dividend-yielding opportunities on our website.

Carna Biosciences Dividend History

Carna Biosciences Dividend Yield

Carna Biosciences current trailing twelve-month (TTM) dividend yield is -%. Interested in purchasing Carna Biosciences stock? Use our calculator to estimate your expected dividend yield:

Carna Biosciences Financial Ratios

P/E ratio-4.18
PEG ratio-0.04
P/B ratio1.77
ROE-37.74%
Payout ratio0.00%
Current ratio9.56
Quick ratio9.17
Cash Ratio8.16

Carna Biosciences Dividend FAQ

Does Carna Biosciences stock pay dividends?
Carna Biosciences does not currently pay dividends to its shareholders.
Has Carna Biosciences ever paid a dividend?
No, Carna Biosciences has no a history of paying dividends to its shareholders. Carna Biosciences is not known for its dividend payments.
Why doesn't Carna Biosciences pay dividends?
There are several potential reasons why Carna Biosciences would choose not to pay dividends to their shareholders:

1. Growth opportunities: Companies, especially in fast-growing industries like technology, reinvest earnings into expansion, R&D, or acquisitions to fuel future growth and increase company value.

2. Tax implications: Not paying dividends can reduce the tax burden on shareholders, who may prefer to defer taxes until selling shares and realizing capital gains.

3. Investor preferences: Some investors prefer companies to reinvest profits for higher long-term returns, particularly those seeking capital appreciation over income.

4. Capital allocation priorities: Companies may allocate cash to pay down debt, fund share buybacks, or invest in projects with higher returns than dividends.

5. Market expectations: In certain sectors, like technology, reinvesting profits for growth and innovation is often prioritized over distributing dividends to shareholders.
Will Carna Biosciences ever pay a dividend?
The decision for a company to pay dividends depends on various factors including its financial performance, growth prospects, capital allocation priorities, and shareholder preferences. While Carna Biosciences has not paid dividends historically and has instead focused on reinvesting its earnings for growth, it's ultimately up to the company's management and board of directors to decide whether to initiate a dividend policy in the future.
Is Carna Biosciences a dividend aristocrat?
Carna Biosciences is not considered a Dividend Aristocrat. The term "Dividend Aristocrat" is typically used to describe a company in the S&P 500 index that has increased its dividend payouts for at least 25 consecutive years.
Is Carna Biosciences a dividend king?
Carna Biosciences is not classified as a "Dividend King". A Dividend King is a company that has managed to increase its dividend payouts for 50 consecutive years or more, which is an even more selective group than the Dividend Aristocrats.
Is Carna Biosciences a dividend stock?
No, Carna Biosciences is not considered a dividend stock. A dividend stock is a stock of a company that regularly pays out dividends to its shareholders.
How to buy Carna Biosciences stocks?
To buy Carna Biosciences you need a brokerage account. Open an account with a reputable brokerage firm that offers access to the stock market. Consider factors such as fees and account minimums.

Place an order: Use the brokerage's trading platform to place an order to buy Carna Biosciences stock.

Remember that buying stocks involves risk, and it's important to carefully consider your investment goals, risk tolerance, and conduct thorough research before making any investment decisions.